Gene mutation can be treated in breast cancer by gene therapy

Breast cancer or carcinoma is mostly characterized by a series of genetic mutations or gene mutations and is therefore ideally place for gene therapy intervention. The aim of gene therapy is to deliver a nucleic acid based drug to either correct or destroy the cells harbouring the genetic aberration. More recently cancer gene therapy has evolved to also encompass delivery of RNA interference technologies, as well as cancer DNA vaccines. However the bottleneck in creating such nucleic acid pharmaceuticals lies in the delivery. Deliverability of DNA is limited as it is circulating nucleases, therefore numerous strategies have been employed to aid with biological transport. This review will discuss some of viral and non viral approaches to breast to breast cancer therapy an present the findings of clinical trials of these therapies in breast cancer patients. Also detailed are some of the most recent developments in non viral approaches to targeting in breast cancer gene therapy. This include transcriptional control, and the development of recombinant, multifunctional bio- inspired system.